Unum, a new cellular immunotherapy company dedicated to antibody-coupled T-cell receptor (ACTR) therapeutics, is leveraging and improving on years of experience with CAR-T cells and construct optimization. In short, ACTR technology enables genetic-programming of T-cells to attack tumor cells in an antibody-directed manner—and Unum’s ACTR constructs are not restricted to a single antigen or narrow set of tumors, but instead can be universally applied to augment any antibody-directed anti-cancer therapy with a cell-surface antigen. Hence the name, derived from e pluribus unum – “out of many, one”. Read more.
It’s no secret that cancer immunotherapy is exploding. The pharma and biotech world is abuzz trying to find the best ways to harness the power of the immune system to fight cancer. Read more.
Raze Therapeutics, a biotechnology company leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways, today announced the closing of a $24 million Series A financing. Read more.
Horizon Pharma plc, a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the presentation of data from a Phase 2 clinical study of ACTIMMUNE® (interferon gamma-1b) treatment in children with Friedreich’s ataxia (FA). Read more.
Synlogic, one of the newer biotech startups to come out of Cambridge, MA, already strung together nearly $30 million when it announced its launch in July. Now it’s topping off that round with some financial support from the Bill & Melinda Gates Foundation to help tackle some of the world’s bigger health problems. Read more.